# Meningioma Genomic Burden Analysis


**Multi-omics analysis demonstrating TMB and CNA as WHO grade biomarkers in meningiomas**

---

## üéØ Project Summary

Comprehensive bioinformatics analysis of 123 meningioma samples identifying **tumor mutational burden (TMB)** and **copy number alterations (CNA)** as quantitative biomarkers for WHO grade stratification.

### Key Findings at a Glance

| Metric | Grade I (n=56) | Grade II/III (n=62) | Fold-Change | p-value | Significance |
|--------|----------------|---------------------|-------------|---------|--------------|
| **TMB** (mut/Mb) | 0.222 | 0.450 | **2.03√ó** | **1.28√ó10‚Åª‚Å¥** | *** |
| **CNA burden** (FGA) | 0.098 | 0.166 | **1.70√ó** | **1.10√ó10‚Åª‚Å¥** | *** |
| **ML Classification** | - | - | AUC=**0.879** | Accuracy=**76.5%** | ‚úì |

*FGA = Fraction Genome Altered*

---

## üìÑ Abstract

**Background:** Meningiomas represent the most common primary intracranial tumor, yet molecular predictors of clinical aggressiveness remain poorly characterized. We conducted a comprehensive multi-omics analysis to investigate whether tumor mutational burden (TMB) and copy number alterations (CNA) correlate with WHO grade classification.

**Methods:** We obtained multi-omics data from 121 meningioma patients (95.0% with somatic mutations, n=115; 100% with copy number data, n=121; 79.3% with protein abundance data, n=96) from the University of Toronto cBioPortal study. Supplementary data included 2 TCGA meningioma samples with whole exome sequencing and 51 meningiomas from Gene Expression Omnibus datasets (GSE43290, n=47; GSE88720, n=14). Clinical annotations included WHO grade (Grade I: n=59; Grade II: n=43; Grade III: n=19; missing: n=2) and recurrence status. Statistical comparisons used the Wilcoxon rank-sum test with significance threshold p<0.05. Machine learning classification was performed using logistic regression, random forest, and XGBoost models on 114 samples with complete genomic data.

**Results:** High-grade meningiomas (WHO Grade II/III, n=62) demonstrated significantly elevated TMB compared to Grade I tumors (n=56): mean 0.450 vs. 0.222 mutations/Mb (fold-change 2.03√ó, p=1.28√ó10‚Åª‚Å¥). Similarly, CNA burden was substantially higher in high-grade tumors: mean fraction genome altered 0.166 vs. 0.098 (fold-change 1.70√ó, p=1.10√ó10‚Åª‚Å¥). Logistic regression achieved the highest classification performance with AUC=0.879 and 76.5% accuracy on the test set (n=34), significantly exceeding the discrimination threshold of AUC>0.70.

**Conclusion:** Genomic variant burden effectively stratifies meningioma aggressiveness and demonstrates clinical utility for grade prediction. These findings support TMB and CNA as quantitative biomarkers for identifying high-risk meningiomas and may guide surveillance protocols and treatment decisions.


## üìä Results Visualization

### Figure 2: TMB by WHO Grade
[View TMB by Grade Figure](https://github.com/yanny-alt/meningioma-genomic-burden/blob/main/results/figures/figure2_tmb_by_grade.pdf)

**High-grade meningiomas show 2.03√ó higher TMB (p<0.001)**

### Figure 3: CNA Burden by WHO Grade  
[View CNA Burden Figure](https://github.com/yanny-alt/meningioma-genomic-burden/blob/main/results/figures/figure3_cna_burden_by_grade.pdf)

**High-grade tumors have 1.70√ó higher CNA burden (p<0.001)**

### Figure 4: Integrated Genomic Landscape
[View Genomic Landscape Figure](https://github.com/yanny-alt/meningioma-genomic-burden/blob/main/results/figures/figure4_integrated_genomic_burden.pdf)

**TMB and CNA correlate with grade severity**

### Figure 5: ML Classification Performance
[View ROC Curves Figure](https://github.com/yanny-alt/meningioma-genomic-burden/blob/main/results/figures/figure5_ml_roc_curves.pdf)

**Logistic regression achieves AUC=0.879 for grade prediction**

---

## üî¨ Methodology

### Data Sources

| Dataset | Samples | Data Types | Source |
|---------|---------|------------|--------|
| **cBioPortal** (UofT) | 121 | Mutations, CNA, Protein | [Study Link](https://www.cbioportal.org/study/summary?id=mng_utoronto_2021) |
| **TCGA** | 2 | WES, CNV segments | [GDC Portal](https://portal.gdc.cancer.gov/) |
| **GSE43290** | 47 | Microarray expression | [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43290) |
| **GSE88720** | 14 | Microarray expression | [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE88720) |

**Total: 123 unique meningioma samples**

### Analysis Pipeline

Data Acquisition ‚Üí Quality Control ‚Üí TMB Calculation ‚Üí CNA Quantification
        ‚Üì                                                      ‚Üì
  Statistical Testing ‚Üê Data Integration ‚Üê Feature Engineering
        ‚Üì
  ML Classification (Logistic Regression, Random Forest, XGBoost)
        ‚Üì
  Visualization & Interpretation


## üî¨ Key Metrics

**TMB Calculation:**
- Total somatic mutations / coding genome size (38 Mb)
- Reported as mutations per megabase (mut/Mb)

**CNA Burden:**
- Fraction of genome altered (FGA)
- Sum of amplified + deleted segments / total genome

**Statistical Tests:**
- Wilcoxon rank-sum test (non-parametric)
- Significance threshold: p < 0.05

**ML Models:**
- 70-30 train-test split
- 5-fold cross-validation
- Performance metrics: AUC, accuracy, sensitivity, specificity

---

## üìà Detailed Results

### Primary Hypothesis (H1): TMB Difference by Grade

**Test:** Wilcoxon rank-sum test  
**Result:** p = 1.28√ó10‚Åª‚Å¥ (highly significant)

| Grade | n | Mean TMB | Median TMB | SD |
|-------|---|----------|------------|-----|
| Grade I | 56 | 0.222 | 0.184 | 0.156 |
| Grade II/III | 62 | 0.450 | 0.398 | 0.312 |

**Interpretation:** High-grade meningiomas have **2.03√ó higher** TMB than low-grade tumors.

### Secondary Hypothesis (H2): CNA Burden Difference by Grade

**Test:** Wilcoxon rank-sum test  
**Result:** p = 1.10√ó10‚Åª‚Å¥ (highly significant)

| Grade | n | Mean FGA | Median FGA | SD |
|-------|---|----------|------------|-----|
| Grade I | 56 | 0.098 | 0.075 | 0.089 |
| Grade II/III | 62 | 0.166 | 0.142 | 0.124 |

**Interpretation:** High-grade meningiomas have **1.70√ó higher** CNA burden.

### Tertiary Hypothesis (H3): ML Classification Performance

| Model | AUC | Accuracy | Sensitivity | Specificity |
|-------|-----|----------|-------------|-------------|
| **Logistic Regression** | **0.879** | **76.5%** | 78.9% | 73.3% |
| Random Forest | 0.845 | 73.5% | 73.7% | 73.3% |
| XGBoost | 0.832 | 70.6% | 68.4% | 73.3% |

**Interpretation:** Genomic burden features achieve **excellent discrimination** (AUC>0.85) for grade classification.

---

## üè¢ Internship Context

This project was completed as part of a **Cancer Genomics Research Internship** at **Genomac Institute Inc.** (July-October 2025).

**Responsibilities:**
- Multi-omics data integration (TCGA, cBioPortal, GEO)
- Statistical analysis and hypothesis testing
- Machine learning model development
- Manuscript preparation and figure generation

**Key Achievements:**
- ‚úÖ Identified TMB and CNA as significant biomarkers (p<0.001)
- ‚úÖ Developed ML classification framework (AUC=0.879)
- ‚úÖ Generated publication-ready manuscript
- ‚úÖ Created reproducible analysis pipeline

---

## üìä Supplementary Materials

### Tables
- **Table S1:** Sample characteristics by dataset and grade
- **Table S2:** Complete TMB and CNA values for all samples
- **Table S3:** Statistical test results (Wilcoxon tests)
- **Table S4:** ML model comparison (3 algorithms)

All supplementary tables available in [`results/tables/`](results/tables/)

### Figures
- **Figure 1:** Study design and cohort overview (planned)
- **Figure 2:** TMB distribution by WHO grade
- **Figure 3:** CNA burden by WHO grade
- **Figure 4:** Integrated genomic burden landscape
- **Figure 5:** ML classification ROC curves

All figures available in [`results/figures/`](results/figures/)

---

## üí° Clinical Implications

### Diagnostic Utility
- **TMB and CNA** provide quantitative measures of tumor aggressiveness
- **ML classification** offers objective grade prediction (76.5% accuracy)

### Potential Applications
1. **Risk Stratification:** Identify high-risk Grade I tumors needing closer monitoring
2. **Treatment Planning:** Guide adjuvant therapy decisions for borderline cases
3. **Surveillance Protocols:** Personalize follow-up intervals based on genomic burden
4. **Clinical Trials:** Stratify patients for targeted therapy studies

### Future Directions
- Validate in independent cohorts
- Integrate with clinical variables (age, sex, location)
- Explore specific driver mutations
- Investigate RNA-seq signatures
  
